Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Company Deals

Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics

Fineline Cube Dec 29, 2025
Company Deals

Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership

Fineline Cube Dec 29, 2025
Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Fineline Cube Dec 23, 2025
Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Policy / Regulatory

NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue

Fineline Cube Dec 29, 2025
Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Fineline Cube Dec 29, 2025
Company Drug

AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect

Fineline Cube Dec 29, 2025
Company Deals

Sciwind Biosciences Partners with SynerK for siRNA Therapeutics Development

Fineline Cube Sep 27, 2022

Hangzhou Sciwind Biosciences Co., Ltd has announced a research partnership with SynerK Inc. The collaboration...

Company Drug

Arctic Vision Administers First Injection of ARVN001 for Uveitis Macular Edema

Fineline Cube Sep 26, 2022

China-based ophthalmic therapies developer Arctic Vision has announced the first injection of triamcinolone acetonide suprachoroidal...

Company Deals

Synthgene Partners with Micor&Nano for Comprehensive Solutions in Nucleic Acid Drugs

Fineline Cube Sep 26, 2022

China-based Jiangsu Synthgene Biotechnology Co., Ltd has entered into a partnership with compatriot firm Micor&Nano...

Company Deals

ThunderBio Secures Funding from Guangzhou LBP for PCR Innovation

Fineline Cube Sep 26, 2022

ThunderBio Innovation Limited, a specialist in droplet microfluidics and molecular diagnostics based in Zhejiang, has...

Company Drug

Fujian Cosunter Receives NMPA Approval for COVID-19 Drug Candidate GST-HG171

Fineline Cube Sep 26, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that it has received approval...

Company Drug

Everest Medicines Gains CDE Approval for EVER001 Phase Ib Study

Fineline Cube Sep 26, 2022

China-based biotech Everest Medicines (HKG: 1952) has announced that it has received approval from the...

Company Medical Device

Boston Scientific Completes First Surgery with RotaPro in China

Fineline Cube Sep 26, 2022

US-based Boston Scientific Corporation (NYSE: BSX) has announced the completion of the first surgery using...

Company

Sihuan Pharmaceutical Reports Decline in Revenues Amid COVID-19 Lockdowns

Fineline Cube Sep 26, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its 2022 interim report for...

Company Deals

Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal

Fineline Cube Sep 26, 2022

China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) has announced a licensing and supply agreement...

Company Drug Legal / IP

HEC Pharma Overturns Patent Decision Against Novartis’ Gilenya

Fineline Cube Sep 23, 2022

China-based generics firm HEC Pharma has managed to overturn a previous final decision in a...

Company Deals

Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293

Fineline Cube Sep 23, 2022

Italy-based Nerviano Medical Sciences S.r.l. (NMS), which is 90% owned by Chinese investment fund SARI...

Company

Moderna’s CMO Expresses Eagerness to Bring mRNA Vaccines to China

Fineline Cube Sep 23, 2022

The Chief Medical Officer (CMO) of US-based Moderna Inc. (NASDAQ: MRNA), Paul Burton, has been...

Company Drug Legal / IP

Novartis Faces Setback in US Patent Battle Over Multiple Sclerosis Drug Gilenya

Fineline Cube Sep 23, 2022

Swiss pharmaceutical giant Novartis AG (SWX: NOVN) has encountered its latest and potentially final setback...

Company Deals

Sino Biopharmaceutical Licenses Lanifibranor for NASH Treatment from Inventiva

Fineline Cube Sep 23, 2022

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary, Jiangsu Chia Tai Tianqing...

Company Drug

Hengrui Medicine’s Dexmedetomidine Nasal Spray Gains Priority Review

Fineline Cube Sep 23, 2022

China’s Center for Drug Evaluation (CDE) has indicated that Hengrui Medicine Co., Ltd’s (SHA: 600276)...

Company Deals

Menarini and OrigiMed Partner on Pan-Cancer Single-Cell Diagnostic Platform

Fineline Cube Sep 23, 2022

Italy’s Menarini Group has formed a strategic partnership with China-based precision medicine firm OrigiMed to...

Company Deals

Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions

Fineline Cube Sep 23, 2022

Jenscare Scientific Co., Ltd., a structural heart disease intervention device maker based in Ningbo, is...

Company Deals

InnoCare Pharma’s IPO Raises $411M for Drug R&D and Platform Upgrade

Fineline Cube Sep 23, 2022

China-based InnoCare Pharma (HKG: 9969) has completed an initial public offering (IPO) of 265 million...

Company Drug

Humanwell’s Generic Clobazam Approved for Lennox-Gastaut Syndrome in China

Fineline Cube Sep 23, 2022

China-based Yichang Humanwell Pharmaceutical Co., Ltd’s generic version of Sanofi’s clobazam (trade name: Frisium) has...

Company Deals

AIM Vaccine Plans IPO to Fund Vaccine R&D and Pipeline Expansion

Fineline Cube Sep 23, 2022

China-based AIM Vaccine Co., Ltd plans to make an initial public offering (IPO) of 9.71...

Posts pagination

1 … 557 558 559 … 602

Recent updates

  • HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology
  • Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics
  • AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy
  • AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect
  • Innovent Biologics Secures NMPA Approval for TABOSUN as First Neoadjuvant Dual‑IO Therapy for MSI‑H/dMMR Colon Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Company Deals

Kleos Health and BioInno Bioscience Forge China Partnership for Exosome Drugs in Orthopedics

Company Drug

AstraZeneca and Ionis’ Eplontersen Wins China Approval for ATTRv-PN as First Gene-Silencing Therapy

Company Drug

AstraZeneca Secures NMPA Approval for Fasenra in EGPA, Demonstrating Superior Steroid-Sparing Effect

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.